Trial intelligence / Profile preview

MSCs for ILD after allo-HSCT

NCT02543073Phase 2Unknown

Sponsor
Nanfang Hospital, Southern Medical University
Start
Sep 2014
Primary completion
Dec 2017
Modality
Stem Cell Therapies
Countries
1
01

Overview

A Phase 2 trial of mesenchymal stem cells in interstitial lung disease (ILD), Bronchiolitis Obliterans Syndrome (BOS), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.

02

Drugs

mesenchymal stem cells
03

Conditions

interstitial lung disease (ILD)Bronchiolitis Obliterans Syndrome (BOS)

Beyond the preview

Go deeper on NCT02543073.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02543073.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call